Sign in
ADMA Stock Price, Chart, Stats & News
ADMA Biologics, Inc.
Save
ADMA Biologics, Inc. (ADMA) does not currently pay a dividend.
2.12B
Market cap
12.87x
Current P/E
9.43x
Forward P/E
ADMA chart
Fundamentals
Gross margin | 57.39% |
Operating margin | 37.52% |
Pretax margin | 35.80% |
Net margin | 28.80% |
Effective tax rate | 19.56% |
ROA | 23.54% |
ROE | 34.98% |
D/E | 0.17x |
Interest coverage ratio | 26.93x |
ADMA valuation
P/E | 12.87x |
P/S | 4.32x |
P/B | 4.61x |
P/CF | 43.68x |
P/FCF | 79.18x |
P/OCF | 43.68x |
PEG | -0.50x |
EV multiple | 11.17x |
About
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI).
Similar securities
Based on sector and market capitalization
Report issue